<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212365</url>
  </required_header>
  <id_info>
    <org_study_id>100416</org_study_id>
    <nct_id>NCT03212365</nct_id>
  </id_info>
  <brief_title>Minimization of Bleeding Related Adverse Drug Events in Plastic &amp; Reconstructive Surgery</brief_title>
  <official_title>Minimization of Bleeding Related Adverse Drug Events in Plastic &amp; Reconstructive Surgery Patients Randomized to Different Postoperative Anticoagulant Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plastic and reconstructive surgeons consistently create large, raw surfaces as part of their&#xD;
      operative procedures. Thus, plastic &amp; reconstructive surgery patients are among those at&#xD;
      highest risk for anticoagulant-associated bleeding adverse drug events (ADEs). This study&#xD;
      seeks to optimize both the safety and effectiveness of post-operative enoxaparin by comparing&#xD;
      aFXa levels, bleeding events, and VTE events among plastic &amp; reconstructive surgery patients&#xD;
      randomized to receive two different enoxaparin dose regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Plastic and reconstructive surgeons consistently create large, raw surfaces as part of their&#xD;
      operative procedures. Thus, plastic &amp; reconstructive surgery patients are among those at&#xD;
      highest risk for anticoagulant-associated bleeding adverse drug events (ADEs). Our&#xD;
      preliminary data has shown that a fixed, or &quot;one size fits all&quot; dose of enoxaparin, an&#xD;
      anticoagulant, can allow a high proportion of patients to have appropriately thinned blood,&#xD;
      measured by anti-Factor Xa (aFXa) levels. Patients with adequate aFXa levels are known to&#xD;
      have significantly decreased venous thromboembolism risk (VTE), which is desirable. However,&#xD;
      30% of patients who receive fixed dose enoxaparin have blood that is too thin. Patients who&#xD;
      are over-anticoagulated are significantly more likely to have ADEs including bleeding&#xD;
      requiring return to the operating room, need for blood transfusion, or death. The optimal way&#xD;
      to dose enoxaparin to minimize ADEs remains unknown. This study seeks to optimize both the&#xD;
      safety and effectiveness of post-operative enoxaparin by comparing aFXa levels, bleeding&#xD;
      events, and VTE events among plastic &amp; reconstructive surgery patients randomized to receive&#xD;
      two different enoxaparin dose regimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Actual">October 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized into one of two groups (enoxaparin 40mg twice daily or enoxaparin 0.5mg/kg twice daily, rounded to the nearest milligram).</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Avoidance of Under-anticoagulation (Peak aFXa &lt;0.2 IU/mL)</measure>
    <time_frame>Four hours following third enoxaparin dose</time_frame>
    <description>Avoidance of under-anticoagulation (peak aFXa &lt;0.2 IU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Avoidance of Over-anticoagulation (Peak aFXa &gt;0.4 IU/mL)</measure>
    <time_frame>Four hours following third enoxaparin dose</time_frame>
    <description>Avoidance of over-anticoagulation (peak aFXa &gt;0.4 IU/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Venous Thromboembolism Events</measure>
    <time_frame>90 days</time_frame>
    <description>Any symptomatic venous thromboembolism events, including deep venous thrombosis or pulmonary embolus occurring within 90 days of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Bleeding Events</measure>
    <time_frame>90 days</time_frame>
    <description>Bleeding events requiring alteration in the course of care within 90 days of surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">295</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep Venous Thrombosis</condition>
  <condition>Pulmonary Embolus</condition>
  <condition>Reconstructive Surgery</condition>
  <arm_group>
    <arm_group_label>Fixed Dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive 40 mg enoxaparin twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Variable Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.5mg/kg enoxaparin twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed dose</intervention_name>
    <description>Participants will receive 40 mg enoxaparin twice daily</description>
    <arm_group_label>Fixed Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Variable dose</intervention_name>
    <description>Participants will receive 0.5mg/kg enoxaparin twice daily</description>
    <arm_group_label>Variable Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  receiving plastic and reconstructive surgery under general anesthesis&#xD;
&#xD;
          -  Expected post-operative stay of 2 days or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to use of enoxaparin&#xD;
&#xD;
          -  intracranial bleeding/stroke&#xD;
&#xD;
          -  Hematoma or bleeding disorder&#xD;
&#xD;
          -  Heparin-induced thrmbocytopenia positive&#xD;
&#xD;
          -  Creatinine clearance less than or equal to 30 mL/min&#xD;
&#xD;
          -  Serum creatinine greater than 1.6 mg/dL&#xD;
&#xD;
          -  epidural anesthesia&#xD;
&#xD;
          -  patients placed on non-enoxaparin chemoprophylaxis regimens&#xD;
&#xD;
          -  gross weight exceeding 150kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Puccini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <results_first_submitted>August 6, 2020</results_first_submitted>
  <results_first_submitted_qc>August 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Christopher Pannucci</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03212365/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fixed Dose</title>
          <description>Participants will receive 40 mg enoxaparin twice daily&#xD;
Fixed dose: Participants will receive 40 mg enoxaparin twice daily</description>
        </group>
        <group group_id="P2">
          <title>Variable Dose</title>
          <description>Participants will receive 0.5mg/kg enoxaparin twice daily&#xD;
Variable dose: Participants will receive 0.5mg/kg enoxaparin twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discharged prior to Xa level</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bled requiring enoxaparin cessation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused study medication</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Initiated heparin infusion on floor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unexpected return to OR</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication distribution error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required epidural placement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>developed acute renal failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fixed Dose</title>
          <description>Participants will receive 40 mg enoxaparin twice daily&#xD;
Fixed dose: Participants will receive 40 mg enoxaparin twice daily</description>
        </group>
        <group group_id="B2">
          <title>Variable Dose</title>
          <description>Participants will receive 0.5mg/kg enoxaparin twice daily&#xD;
Variable dose: Participants will receive 0.5mg/kg enoxaparin twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="144"/>
            <count group_id="B3" value="295"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="15.6"/>
                    <measurement group_id="B2" value="52.7" spread="14.8"/>
                    <measurement group_id="B3" value="50.8" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American/Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Avoidance of Under-anticoagulation (Peak aFXa &lt;0.2 IU/mL)</title>
        <description>Avoidance of under-anticoagulation (peak aFXa &lt;0.2 IU/mL)</description>
        <time_frame>Four hours following third enoxaparin dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose</title>
            <description>Participants will receive 40 mg enoxaparin twice daily&#xD;
Fixed dose: Participants will receive 40 mg enoxaparin twice daily</description>
          </group>
          <group group_id="O2">
            <title>Variable Dose</title>
            <description>Participants will receive 0.5mg/kg enoxaparin twice daily&#xD;
Variable dose: Participants will receive 0.5mg/kg enoxaparin twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Avoidance of Under-anticoagulation (Peak aFXa &lt;0.2 IU/mL)</title>
          <description>Avoidance of under-anticoagulation (peak aFXa &lt;0.2 IU/mL)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6"/>
                    <measurement group_id="O2" value="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Avoidance of Over-anticoagulation (Peak aFXa &gt;0.4 IU/mL)</title>
        <description>Avoidance of over-anticoagulation (peak aFXa &gt;0.4 IU/mL)</description>
        <time_frame>Four hours following third enoxaparin dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose</title>
            <description>Participants will receive 40 mg enoxaparin twice daily&#xD;
Fixed dose: Participants will receive 40 mg enoxaparin twice daily</description>
          </group>
          <group group_id="O2">
            <title>Variable Dose</title>
            <description>Participants will receive 0.5mg/kg enoxaparin twice daily&#xD;
Variable dose: Participants will receive 0.5mg/kg enoxaparin twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Avoidance of Over-anticoagulation (Peak aFXa &gt;0.4 IU/mL)</title>
          <description>Avoidance of over-anticoagulation (peak aFXa &gt;0.4 IU/mL)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2"/>
                    <measurement group_id="O2" value="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Venous Thromboembolism Events</title>
        <description>Any symptomatic venous thromboembolism events, including deep venous thrombosis or pulmonary embolus occurring within 90 days of surgery</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose</title>
            <description>Participants will receive 40 mg enoxaparin twice daily&#xD;
Fixed dose: Participants will receive 40 mg enoxaparin twice daily</description>
          </group>
          <group group_id="O2">
            <title>Variable Dose</title>
            <description>Participants will receive 0.5mg/kg enoxaparin twice daily&#xD;
Variable dose: Participants will receive 0.5mg/kg enoxaparin twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Venous Thromboembolism Events</title>
          <description>Any symptomatic venous thromboembolism events, including deep venous thrombosis or pulmonary embolus occurring within 90 days of surgery</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66"/>
                    <measurement group_id="O2" value="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Bleeding Events</title>
        <description>Bleeding events requiring alteration in the course of care within 90 days of surgery</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fixed Dose</title>
            <description>Participants will receive 40 mg enoxaparin twice daily&#xD;
Fixed dose: Participants will receive 40 mg enoxaparin twice daily</description>
          </group>
          <group group_id="O2">
            <title>Variable Dose</title>
            <description>Participants will receive 0.5mg/kg enoxaparin twice daily&#xD;
Variable dose: Participants will receive 0.5mg/kg enoxaparin twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Bleeding Events</title>
          <description>Bleeding events requiring alteration in the course of care within 90 days of surgery</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <desc>Study team performed chart review and made mandatory phone contact with patients at 90 days to identify adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fixed Dose</title>
          <description>Participants will receive 40 mg enoxaparin twice daily&#xD;
Fixed dose: Participants will receive 40 mg enoxaparin twice daily</description>
        </group>
        <group group_id="E2">
          <title>Variable Dose</title>
          <description>Participants will receive 0.5mg/kg enoxaparin twice daily&#xD;
Variable dose: Participants will receive 0.5mg/kg enoxaparin twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Pannucci, MD</name_or_title>
      <organization>University of Utah</organization>
      <phone>801 581 2121</phone>
      <email>christopher.pannucci@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

